We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Method Quickly Identifies Antibiotic-Resistant Acinetobacter

By Biotechdaily staff writers
Posted on 11 Dec 2007
Acinetobacter baumannii, a bacterium widely found on our skin and in the environment, has now become a major threat in hospitals where it can cause serious infections, such as pneumonia in severely ill patients. More...
The new types Acinetobacter are resistant to nearly all antibiotics and three resistant strains are currently circulating in the United Kingdom. A molecular method for identifying the bacteria has been successfully developed.

The method, designed by the Health Protection Agency (London, UK), was successfully implemented by medical scientists at the Royal Free Hospital (Hampstead, UK). It is a quick and accurate means of identifying which strain of the bacterium is infecting a patient. The multiplex-polymerase chain reaction (PCR), based on identifying unique gene sequences in the bacteria, has the potential to be developed as a rapid screening tool for intensive care units in other parts of the country. It should eventually lead to better patient management with faster and more appropriate treatments for individuals and prompt control of infections to reduce the risk of transmission to other patients

The drug-resistant strains of the bacteria are especially dangerous in intensive care units where, as well as causing pneumonia, they can infect wounds, or cause urinary tract infections. "Some of these new strains of A. baumannii, known as epidemic clones, can spread rapidly and widely between patients and have the potential to cause outbreaks,” said Kerry Williams of the Royal Free Hospital. "We currently encounter two of them at our hospital, so we need a reliable and rapid means of identifying and discriminating between the different clones. We can now get a result from a patient's sample in just four hours. The test also allows us to predict how likely we are to be facing an outbreak.”

"Like MRSA, A. baumannii can be found on the skin without actually causing an infection. The new test is important because it means we can rapidly identify patients who are colonized with drug-resistant strains of the bacteria so that special infection control measures can be put in place. The patient can quickly be isolated if necessary,” added Miss Williams of the Royal Free Hospital. "This reduces the risk of transmission to other patients and the possibility of an outbreak occurring. The ability to distinguish between the clones circulating is also important because it allows us to monitor transmission in our hospital.”

Currently all the Royal Free Hospital strains of bacteria are sent to a reference laboratory for typing by a method called pulsed field gel electrophoresis. The new test, called multiplex-PCR, gives results comparable to the ones produced by the reference laboratory.

The method was described at the Federation of Infection Societies Conference 2007 in Cardiff (Wales,UK), on November 28, 2007.


Related Links:
Health Protection Agency
Royal Free Hospital

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.